HSPB1 (Heat Shock Protein Family B Member 1), commonly known as Hsp27 or HspB1, is a member of the small heat shock protein (sHsp) family. Unlike larger heat shock proteins, sHsps lack ATPase activity and function primarily as ATP-independent chaperones that prevent protein aggregation and hold misfolded proteins in a state competent for refolding by Hsp70/Hsp70 family members [3]. Hsp27 is expressed in virtually all cell types and is particularly important in neural tissue, where it provides crucial protection against various stresses including oxidative stress, proteotoxic stress, and apoptotic stimuli. Mutations in HSPB1 are linked to peripheral neuropathy and motor neuron disease, highlighting its essential role in neuronal maintenance [1][2].
| HSPB1 — Heat Shock Protein Family B Member 1 |
|---|
| Gene Symbol | HSPB1 |
| Common Name | Hsp27, HspB1 |
| Full Name | heat shock protein family B member 1 |
| Chromosome | 7q11.23 |
| NCBI Gene ID | 3315 |
| Ensembl ID | ENSG00000178462 |
| OMIM | 604533 |
| UniProt ID | P04792 |
| Associated Diseases | Charcot-Marie-Tooth Disease, [ALS](/diseases/als), [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Peripheral Neuropathy |
¶ Domain Architecture
Hsp27 is a 205-amino acid protein with a molecular mass of approximately 27 kDa. The protein contains two key regions:
- N-terminal variable region (1-100 aa): Contains the WDPF motif and a range of N-terminal extensions unique to each sHsp
- α-crystallin domain (100-175 aa): The conserved core domain shared by all sHsps, approximately 80 amino acids in length
- C-terminal extension (175-205 aa): Flexible tail involved in oligomerization
Hsp27 forms large oligomers, typically 12-32 subunits, through interactions involving both the N-terminal and α-crystallin domains. This oligomeric state is dynamic and can change in response to stress:
- Basal state: 16-24 subunit oligomers
- Stressed state: Smaller oligomers (8-12 mers) with increased chaperone activity
- Phosphorylated state: Disassembly to dimers/tetramers
Hsp27 is phosphorylated at three serine residues (Ser15, Ser78, Ser82) by MAP kinase-activated protein kinase-2 (MAPKAPK-2). Phosphorylation triggers oligomer disassembly and is a key regulatory mechanism.
Hsp27 functions as an ATP-independent chaperone with several key activities:
- Aggregation prevention: Binds unfolding proteins to prevent their aggregation
- Holding function: Keeps misfolded proteins in a state competent for Hsp70-mediated refolding
- Native state stabilization: Stabilizes proteins in their native conformations
- Sequestration: Can sequester irreversibly damaged proteins into aggresomes
Hsp27 is a potent anti-apoptotic protein through multiple mechanisms:
- Caspase inhibition: Directly inhibits caspase-3 and caspase-9
- ** cytochrome c sequestration**: Prevents cytochrome c release from mitochondria
- DIAP1 stabilization: Stabilizes XIAP (inhibitor of apoptosis proteins)
- ASK1 inhibition: Blocks apoptosis signal-regulating kinase 1 (ASK1) signaling
- NF-κB activation: Promotes survival signaling
Hsp27 plays a crucial role in cytoskeletal maintenance:
- Actin dynamics: Regulates actin polymerization and depolymerization
- Intermediate filament assembly: Supports keratin and vimentin networks
- Tubulin protection: Protects microtubules from oxidative damage
- Motility: Supports actin-based cell migration
Through its chaperone function, Hsp27 helps manage oxidative stress:
- Redox-sensitive chaperone: Activity modulated by cellular redox state
- Antioxidant function: Protects antioxidant enzymes
- Thiol oxidation prevention: Prevents damaging protein oxidation
¶ Expression and Regulation
Hsp27 is ubiquitously expressed with highest levels in:
- Nervous system: Brain, spinal cord, peripheral nerves
- Muscle: Skeletal muscle, cardiac muscle
- Epithelial tissues: Skin, lung, gastrointestinal tract
- Reproductive system: Testis, ovary
In the central nervous system, Hsp27 is expressed in:
- Neurons: Pyramidal neurons of cortex, hippocampal neurons
- Astrocytes: Particularly in white matter
- Oligodendrocytes: Moderate expression
- Microglia: Low baseline, induced upon activation
Hsp27 expression is regulated at multiple levels:
- Transcriptional: Heat shock factor (HSF1)-mediated transcription
- Translational: mRNA stability and translation efficiency
- Post-translational: Phosphorylation and oligomerization state
- Cellular localization: Can shift between cytosolic and nuclear compartments
Hsp27 is intimately involved in ALS pathogenesis:
- Mutations: Rare HSPB1 mutations cause inherited ALS
- SOD1 aggregation: Hsp27 can inhibit mutant SOD1 aggregation
- TDP-43 pathology: Interacts with TDP-43 aggregates
- Axonal transport: Protects microtubule-dependent transport
The neuroprotective mechanisms in ALS include [7]:
- Inhibition of caspase activation
- Protection against oxidative stress
- Maintenance of axonal transport
- Management of protein aggregates
In AD, Hsp27 provides multiple protective functions [13]:
- Aβ interaction: Can bind Aβ peptides and prevent aggregation
- Tau protection: Helps protect tau from hyperphosphorylation
- Synaptic protection: Protects synapses from degeneration
- Neuroinflammation: Modulates glial responses
Hsp27's role in PD involves [12]:
- α-Synuclein interaction: Binds α-synuclein and prevents aggregation
- Mitochondrial protection: Protects dopaminergic neurons from mitochondrial toxins
- Autophagy enhancement: Can promote autophagic clearance
- ER stress protection: Complements ER chaperone systems
HSPB1 mutations are a known cause of CMT2F, an inherited peripheral neuropathy:
- Axonal degeneration: Mutations cause progressive axonal loss
- Sensory and motor dysfunction: Leads to weakness and atrophy
- Onset age: Variable, typically adolescence to adulthood
- Phenotypic variability: Even within families
Pathogenic mechanisms include:
- Impaired chaperone activity
- Altered oligomerization
- Loss of anti-apoptotic function
- Cytoskeletal disruption
- Hereditary spastic paraplegia: Similar phenotype to CMT
- Guillain-Barré syndrome: Autoimmune neuropathy
- Diabetic neuropathy: Metabolic neuropathy
- Hsp27 inducers: Arimoclomol (investigational ALS drug)
- Hsp90 inhibitors: 17-AAG, ganetespib (indirect Hsp27 upregulation)
- Proteostasis modulators: Boost Hsp70/Hsp90 systems
AAV-mediated Hsp27 overexpression has been explored for:
- ALS models
- Parkinson's disease models
- Ischemic brain injury
Hsp27 enhancement may synergize with:
- Antioxidants: N-acetylcysteine, edaravone
- Autophagy modulators: Rapamycin, trehalose
- Anti-apoptotic drugs: XIAP mimetics
Hsp27 knockout mice show:
- Viable: No embryonic lethality
- Stress sensitivity: Increased sensitivity to various stresses
- Impaired recovery: Slowed recovery from stress
- Cytoskeletal abnormalities: Mild cytoskeletal defects
Hsp27 overexpression protects against:
- Ischemic injury: Stroke models
- Neurodegeneration: ALS and PD models
- Chemotherapy toxicity: Vincristine neuropathy
Zebrafish hspB1 mutants show developmental abnormalities
flowchart TD
A["Cellular Stress"] --> B["HSF1<br/>Activation"]
B --> C["Hsp27<br/>Transcription"]
C --> D["Oligomer<br/>Assembly"]
D --> E["Direct<br/>Chaperone Activity"]
E --> F["Prevent<br/>Aggregation"]
F --> G["Hsp70<br/>Handoff"]
G --> H["Refolding"]
D --> I["Anti-apoptotic<br/>Activity"]
I --> J["Inhibit<br/>Caspases"]
J --> K["Block<br/>Cytochrome c"]
K --> L["Prevent<br/>Apoptosis"]
M["Neurodegeneration"] --> N["Protein<br/>Aggregation"]
N --> O["Hsp27<br/>Sequestration"]
O --> P["Aggresome<br/>Formation"]
P --> Q["Autophagic<br/>Clearance"]
R["Oxidative Stress"] --> S["Protect<br/>Enzymes"]
S --> T["Maintain<br/>Redox Balance"]
style M fill:#ffcdd2
style L fill:#c8e6c9
style Q fill:#fff3e0
| Partner |
Function |
| Hsp70/Hsp70 |
Chaperone cooperation |
| Hsp90 |
Co-chaperone network |
| Caspase-3 |
Direct inhibition |
| Cytochrome c |
Sequestration |
| α-Synuclein |
Aggregation prevention |
| Tau |
Phosphorylation regulation |
| SOD1 |
Aggregation prevention |
| TDP-43 |
Aggregate clearance |
- p38 MAPK pathway: Phosphorylation
- ASK1 pathway: Apoptosis regulation
- NF-κB pathway: Survival signaling
- Serum Hsp27: Potential biomarker in some conditions
- CSF levels: May reflect CNS pathology
- Expression changes: Therapeutic target engagement
Arimoclomol, which upregulates Hsp27, has been in ALS clinical trials
- Benndorf et al. (2001) — HSPB1 mutation in CMT2
- Ackerley et al. (2006) — Hsp27 mutation in spastic paraplegia
- Carra et al. (2014) — sHsp review
- Sharp et al. (2013) — Hsp27 therapeutic potential in ALS
- Wyttenbach et al. (2002) — Hsp27 and Aβ toxicity
- Arrigo et al. (1998) — sHsp redox regulation